COMMUNIQUÉS West-GlobeNewswire

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
22/10/2026
MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026
22/10/2026
Company to host conference call and webcast on Thursday, November 5 at 4:30 p.m. ET FocalTherics ™ to Announce Third Quarter 2026 Financial Results on November 5, 2026 Company to host conference call and webcast on [...]
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
22/10/2026
Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027 MELBOURNE, Australia, Oct. 22, 2026 ( [...]
VisCardia Announces Publication of RECOVER-HF Pilot Trial in JACC: Heart Failure
22/10/2026
Publication marks a milestone for VisONE™ cardiac diaphragm support as enrollment continues in the RECOVER-HF pivotal IDE trial PORTLAND, Ore., Oct. 22, 2026 (GLOBE NEWSWIRE) -- VisCardia, Inc. today announced the [...]
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar
22/10/2026
Patient advocacy initiative expands its reach with a nationally recognized voice on health, resilience and informed treatment decisions TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX [...]
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
22/10/2026
GAITHERSBURG, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2026 [...]
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22/10/2026
WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
22/10/2026
Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Highlights Collaboration aims to accelerate precision oncology research in Australia Combines Fortrea’s [...]
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
22/10/2026
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial on Friday, October [...]
A Race Against Blindness Celebrates Recent Fundraiser Winners During Blindness Awareness Month
22/10/2026
Nonprofit highlights winners and launches its popular Build Your Own Adventure Van fundraiser to advance research for childhood blindness GILBERT, Ariz., Oct. 22, 2026 (GLOBE NEWSWIRE) -- In recognition of October's [...]
Foundation for Sarcoidosis Research Welcomes Nine New Members to the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA)
22/10/2026
The FSR-GSCA unites 55 leading clinics worldwide in a powerful, shared commitment to advancing research, transforming patient care, and accelerating progress toward a cure CHICAGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- The [...]
Nordic Naturals Experts Share the Four Questions Every Consumer Should Ask About Their Supplements
22/10/2026
Not all supplements are created equal; No. 1 omega-3 brand‡ sets the bar for standards on purity, potency, freshness, and absorption Watsonville, CA, Oct. 22, 2026 (GLOBE NEWSWIRE) -- With the supplement market flooded [...]
IQity Draws Strong Surgeon Interest at First Exhibition Debut, AAO 2026
22/10/2026
Integrated workflow of IQ-Meter, IQ-SurgiView and IQ-Flow demonstrated live for the first time; surgeons single out robotic visualization, console-free ECP and a compact all-in-one diagnostic suited to office-based [...]
SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI
22/10/2026
New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital [...]
Walden Biosciences Announces Positive Data from Diabetic Kidney Disease Cohorts in Ongoing Phase 2 Study of WAL0921
22/10/2026
Six of 12 evaluable participants receiving WAL0921 treatment experienced proteinuria (UACR) reduction greater than 20 percent; median 32.4 percent UACR reduction among responders Initial clinical results provide proof- [...]
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
22/10/2026
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protection Structural modeling provides new insight into izicopan’s differentiated molecular profile Jena, Germany, Oct. 22, 2026 [...]
Regulated information: Disclosure of a transparency notification from Aberdeen Group plc
22/10/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 22 October 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the [...]
One04 Therapeutics presents positive interim Phase 1 data for CPV-104 in C3 glomerulopathy in ASN Kidney Week late-breaker
22/10/2026
Met predefined primary and secondary objectives for the interim analysis CPV-104 was generally well tolerated in healthy volunteers and patients with C3 glomerulopathy (C3G) Exploratory analyses in patients with C3G [...]
Guerbet : Chiffre d’affaires au 30 septembre 2026.
22/10/2026
Chiffre d’affaires au 30 septembre 2026 Une activité conforme aux anticipations du Groupe Chiffre d’affaires au 30 septembre 2026 de 573,8 M€, en repli de 1,3% à TCC 1 et périmètre comparable 2 ; hors Chine, une [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum